Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease^[1][2].

Sotrovimab 可以中和 SARS-CoV-2 和 SARS-CoV，但不能直接阻断病毒受体结合^[2]。
Sotrovimab (100 μg/mL, 注射入培养基, 持续 200 s,v=30 μL/min) 能有效结合表面表达的 SARS-CoV-2 S^[3]。
Sotrovimab (0.3 ng/mL-20 mg/mL; 30 min) 对 SARS-CoV-2 伪型病毒具有体外中和作用，对Alpha、Beta、Gamma、Delta 和 Kappa 变种病毒的 IC₅₀分别为 187.2 ng/mL、71.9 ng/mL、73.11 ng/mL、51.3 ng/mL 和 118.64 ng/mL^[3]。

Sotrovimab (5 mg/kg, 10 mL; 经静脉导管给药; 单次剂量) 可对雌性食蟹猴肺部的易感变异进行长达 28 天的保护性暴露^[3]。

2423014-07-5

Please store the product under the recommended conditions in the Certificate of Analysis.